KERX Financial Facts
Total research and development: 8.67MNet loss: -41.7M
See Full Income Statement
Other assets, net: 1.02M
Deferred revenue: 0
See Full Balance Sheet
Keryx Biopharmaceuticals Inc. (KERX) Earnings
|
Expand Research on KERX
| Next EPS Date | N/A | EPS Growth Rate | N/A |
|---|---|---|---|
| Average EPS % Beat Rate | -97.1% | Revenue Growth Rate | N/A |
| Average % Move 1-Wk after EPS | -2.5% | Normal Earnings Time | Before Open |
| Date | Qtr | EPS | Cons. | Surprise | Revs | Cons. | Gd. | 1-Week % | 1-Day % | Details | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 5/8/12 | Q112 | -$0.13 | -$0.12 | -$0.01 | N/A | N/A | N/A |  | | Details | |
2/25/16  |
 |
Q415 | -$0.36 | -$0.25 | -$0.11 | $5.8M | $5.68M | N/A | | | Details |
| 11/9/16 |
|
Q316 | -$0.39 | -$0.20 | -$0.19 | $6.3M | $5.37M | N/A | | | Details |
| 2/29/12 |
|
Q411 | -$0.12 | -$0.14 | +$0.02 | N/A | N/A | N/A | | | Details |
| 5/4/17 | |
Q117 | -$0.21 | -$0.20 | -$0.01 | $11.8M | $10.27M | = | | | Details |
| 11/4/13 | Q313 | -$0.19 | -$0.11 | -$0.08 | N/A | $2.22M | N/A | | | Details | |
| 2/27/15 |
|
Q414 | -$0.44 | -$0.37 | -$0.07 | $569K | $1.39M | N/A | | | Details |
| 5/7/13 | Q113 | -$0.03 | -$0.01 | -$0.02 | $7M | $5.83M | N/A | | | Details |
